All News
Filter News
Found 143 articles
-
Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors
11/10/2022
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced clinical data from phase 1b/2 studies of its anti-CTLA-4 antibody candidate, ADG116, in two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting taking place in Boston.
-
Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November
10/11/2022
Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced that it will present clinical data from phase 1b/2 studies of its anti-CTLA-4 antibody candidate, ADG116, at the upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting taking place November 8-12 in Boston.
-
Increased Awareness of the Netherton Syndrome is Expected to Drive Netherton Syndrome Market Growth by 2030 | Reports and Data
9/28/2022
The latest market analysis report published by Reports and Data, titled ‘Global Netherton Syndrome Market – Forecast to 2030,’ thoroughly examines the Netherton Syndrome industry to provide essential data & information for the targeted readers
-
Rising Demand for Medicines Related to the Treatment of Follicular Lymphoma is Expected to Drive Follicular Lymphoma Treatment Market Growth by 2030 | Reports and Data
9/28/2022
The latest market analysis report published by Reports and Data, titled ‘Global Follicular Lymphoma Treatment Market – Forecast to 2030,’ thoroughly examines the Follicular Lymphoma Treatment industry to provide essential data & information for the targeted readers.
-
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors
9/10/2022
Adagene Inc., a company transforming the discovery and development of novel antibody-based therapies, announced the publication of data showing the best-in-class potential of ADG126, a masked, anti-CTLA-4 SAFEbody®.
-
Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates
8/30/2022
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the six months ended June 30, 2022 and provided corporate updates.
-
Robot Assisted Surgical Systems Market Growth, Key Players Analysis on Presents and Future Statistics till 2027
8/25/2022
The Global Robot Assisted Surgical Systems Market is forecast to reach USD 17.80 billion by 2027.
-
Rising Prevalence of Alzheimer's Disease and Related Disorders is Expected to Drive the Growth of Lewy Body Dementia Treatment Market till 2030 - Reports and Data
8/10/2022
The latest market analysis report published by Reports and Data, titled ‘Global Lewy Body Dementia Treatment Market – Forecast to 2030,’ thoroughly examines the Lewy Body Dementia Treatment industry to provide essential data & information for the targeted readers
-
Osteomyelitis Treatment Market Complete Report On Industry Size, Share, Growth and Trends till 2030
7/25/2022
Forecast to 2030,’ thoroughly examines the Osteomyelitis Treatment industry to provide essential data & information for the targeted readers.
-
High Incidence of Knee Problems Can Expect to Drive Asia Pacific Knee Replacement Implants Market Growth
7/13/2022
The global knee replacement implants market size is expected to reach USD 17.45 Billion in 2030 and register a revenue CAGR of 5.3% over the forecast period, according to latest report by Reports and Data.
-
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million
6/29/2022
Adagene Inc. announced that its board of directors has authorized a share repurchase program under which, Adagene may repurchase up to US$10 million of its ordinary shares in the form of American depositary shares, subject to the relevant rules under the Securities Exchange Act of 1934, as amended, and the Company’s insider trading policy.
-
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
5/26/2022
Adagene Inc., a company transforming the discovery and development of novel antibody-based therapies, announced the publication of data showing the potential best-in-class safety profile of its anti-CTLA-4 monoclonal antibody, ADG126.
-
Adagene to Participate in Investor Conferences in May and June 2022
5/12/2022
Adagene Inc. announced that members of the company’s management will participate in the following upcoming investor conferences.
-
Adagen Market Analysis, Development, Opportunities, Future Growth and Business Prospects by Forecast To 2027
5/6/2022
The data has been collected through extensive primary and secondary research and is validated by experts in the industry.
-
Antiviral Drugs Market Analysis 2022-2030- Introduction Of New, Improved, And Innovative Drug Formulations Is A Key Factor Driving Market Revenue Growth
4/26/2022
Rising incidence of influenza, respiratory syncytial virus activity, and other viral respiratory infections is a key factor driving market revenue growth.
-
Air Ambulance Service Market Size 2022-2030- Increasing Technological Advancements In Air Ambulance Services Is A Key Revenue Growth-Driving Factor
4/26/2022
Rising incidence of trauma, stroke, and heart attack is expected to increase demand for air medical services, which is one of the key factors driving market revenue growth.
-
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022
4/8/2022
Adagene Inc., a company transforming the discovery and development of novel antibody-based therapies, announced preclinical data showcasing the potential first and best-in-class profile of new antibody candidates.
-
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update
3/31/2022
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the full-year ended December 31, 2021, and provided corporate updates.
-
Adenosine Deaminase Deficiency Market Trends, Revenue, Key Players, Growth, Share and Forecast Till 2027
3/28/2022
The industry analysis report is considered a valuable source of information about the global Adenosine Deaminase Deficiency industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.
-
It was a busy week for clinical trial announcements. Here's a look.